LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
Ballerup, June 28, 2022 – LEO Pharma today announced the appointment of Elisabeth Svanberg – MD, PhD – as new member of its Board of Directors.
Elisabeth Svanberg currently serves as member of the Board of Directors at Amolyt SA, Galapagos SA and Egetis Therapeutics AB. Since 2016 she has served as Chief Development Officer at Ixaltis SA and since 2020 as Chief Medical Officer at Kuste Biopharma. She has previously held global positions with Janssen Pharmaceuticals (a Johnson & Johnson company), Bristol-Myers Squibb and MERCK-SERONO.
- Elisabeth Svanberg brings extensive biotech and pharmaceutical experience from a multinational environment, that will be of great value for LEO Pharma in setting direction for launching new innovative treatments on the global market and in creating future growth. I look much forward to working together with Elisabeth going forward, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.
Elisabeth Svanberg has demonstrated success in product development in different therapeutic areas and development phases regulated by both FDA, EMA, CFDA and PMDA. She is recognized for successfully translating strategic goals into practical implementation by establishing high performing cross-functional teams in global networks and championing collaboration across functions to accelerate business results
- LEO Pharma is at a very exciting time of its development going from a traditional pharmaceutical company to a globally focused player in the innovative biotech space. It is an exciting time to join the Board of Directors and I look forward to contribute to paving the way for future success, said Elisabeth Svanberg.
Elisabeth Svanberg is Associated Professor of Surgery and holds a MD (MD License 1990) and a PhD in Surgical Sciences from University of Gothenburg, Sweden.
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma appoints new Executive Vice President of Global Product Supply3.8.2022 14:29:55 CEST | Press release
Ballerup, Denmark, August 03, 2022 – LEO Pharma A/S announced today the appointment of Sven Hauptmann as its new Executive Vice President of Global Product Supply, effective August 1, 2022. Sven joins LEO Pharma with more than 25 years of international experience from Roche where he has held numerous leadership positions within supply chain and manufacturing. He comes with a strong track record delivering world-class results e.g., as Site Lead for Roche’s production site in Ireland, Vice President for Small Molecules Manufacturing and most recently as Senior Vice President for Global Drug Product Manufacturing. Sven holds a Ph.D. in Chemistry from the Technical University in Darmstadt, Germany and an Executive MBA from Northwestern University – Kellogg School of Management. “I am delighted and proud to welcome Sven to LEO Pharma. I strongly believe he will bring significant value to our business and drive the transformation agenda in our global product supply as we progress on our ambi
LEO Pharma strengthens its commercial organization2.6.2022 13:00:00 CEST | Press release
Ballerup – June 2, 2022 – As part of LEO Pharma’s transformation towards becoming a global leader in medical dermatology, the company today announced a refocused commercial structure to support building a more simple, agile, and competitive company.
LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative21.4.2022 14:00:00 CEST | Press release
The validation confirms that LEO Pharma’s climate targets to reduce green-house gas emissions are in line with the Paris Agreement.
LEO Pharma presents new interim long-term safety and efficacy data for Adtralza® (tralokinumab) in moderate-to-severe atopic dermatitis at the 2022 AAD Annual Meeting25.3.2022 12:00:00 CET | Press release
3.5-year interim analysis from ECZTEND, an open-label, 5-year extension trial, showed the overall safety profile of tralokinumab was consistent with that observed in the parent trials, with no new safety signals.1 Efficacy analysis showed sustained improvement across a variety of endpoints – including extent and severity of atopic dermatitis, itch severity, and quality of life – in adult patients treated with Adtralza for up to 3 years.1
LEO Pharma announces annual results 202117.3.2022 13:00:00 CET | Press release
A year of investments and transformation of the global organization, progressing on strategy towards 2030
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom